Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the topline results of an independent report from microbiology specialists, JMI Laboratories. The report shows that iclaprim is effective in vitro against a range of Gram-positive bacteria, including Staphylococcus aureus, one of the key causes of acute bacterial skin and skin structure infection (ABSSSI) and hospital-acquired bacterial pneumonia (HABP).
The recently completed laboratory study tested iclaprim against more than 2,000 bacterial strains, including 1,178 strains of Staphylococcus aureus collected in 2014 from patients in the U.S.A., Europe, Asia Pacific, and Latin America. Iclaprim was found to be 16-fold more potent than trimethoprim, the only other antibacterial dihydrofolate reductase inhibitor (DHFRi) administered alone in today’s market.
Reported minimum inhibitory concentrations (MICs) demonstrated that iclaprim is active against Staphylococcus aureus at very low concentrations. The MIC50, the minimum concentration of iclaprim required to kill 50% of tested bacteria, was 0.06 mcg/ml and the MIC90, the minimum concentration of iclaprim required to kill 90% of tested bacteria, was 0.12 mcg/ml. Comparing this to data for other antibiotics against the same 1,178 strains of Staphylococcus aureus, 1 mcg/ml of vancomycin and 1 mcg/ml of linezolid was required to meet the MIC50 and MIC90 levels. Against methicillin-resistant Staphylococcus aureus (MRSA), iclaprim was also highly active: the MIC50 was 0.06 mcg/ml and the MIC90 was 0.5 mcg/ml.
The tests were conducted according to Clinical and Laboratory Standards Institute (CLSI) methods. CLSI develops clinical laboratory testing standards based on input from and consensus among industry, government, and health care professionals around the world.
Dr. David Huang, Chief Medical Officer at Motif, commented: “These encouraging new results confirm the Board’s confidence in developing iclaprim to treat ABSSSI and HABP. We believe that iclaprim will prove to be an important option for treating these life threatening infections where currently available treatments are not fully effective due to resistance or side effects.”
Motif Bio plc
Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
MC Services AG (TRADE PR)
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / John Treacey
+44 (0) 207 533 7727
Northland Capital Partners (Broker)
+44 (0) 207 382 1100
Plumtree Capital Limited (Financial Advisor)
+44 (0) 207 183 2493
Yellow Jersey PR
+44 (0) 7768 537 739
Notes to Editors
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.